Search clinical trials for: Intermediate risk myelofibrosis

Total 16561 results

Ryvu Therapeutics SA

Not yet recruiting

RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis (POTAMI-61)

Myelofibrosis

Italy, Poland
National Taiwan University Hospital

Recruiting

Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk Myelofibrosis

Pre-fibrotic Myelofibrosis

Taiwan
Geron Corporation

Recruiting

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Myelofibrosis

United States, Australia, Italy, India, United Kingdom, Israel, Taiwan, Poland, Malaysia, Argentina, Spain, Turkey, Belgium, Germany, Austria, Brazil, Bulgaria, Colombia, Denmark, France, Georgia, Hungary, Korea, Republic of, Portugal, ... and more
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Completed

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Canada
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis

Myelofibrosis

China
Celgene

Active, not recruiting

A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Primary Myelofibrosis

Japan
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.

Myelofibrosis

China
Geron Corporation

Completed

Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor

Myelofibrosis

United States, France, Italy, United Kingdom, Belgium, Germany, Taiwan, Spain, Israel, Korea, Republic of, Canada
Novartis Pharmaceuticals

Completed

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Bone Marrow Diseases | Hematologic Diseases | Blood Coagulation Disorders | Hemorrhagic Disorders | Primary Myelofibrosis | Myeloproliferative Disorders | Polycythemia Vera | Thrombocytosis | Essential Thrombocythemia | Blood Platelet Disorders

United Kingdom, Belgium, Canada, France, Australia, Netherlands, Spain, Denmark, Ireland, Italy, Germany
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)

Myelofibrosis

Italy, United States, Canada, Germany
Washington University School of Medicine
CTI BioPharma

Withdrawn

Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Myelofibrosis | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Myeloproliferative Neoplasm | Atypical Chronic Myeloid Leukemia
Sanofi

Completed

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis (JAKARTA)

Hematopoietic Neoplasm

Austria, Germany, Italy, Spain, United Kingdom, France, Belgium, Israel, Sweden, Australia, United States, Lithuania, Portugal, Korea, Republic of, Singapore, Taiwan, Mexico, Brazil, Canada, Hungary, Ireland, Poland, Romania, Russian... and more
Sanofi

Completed

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Myelofibrosis

Japan
Millennium Pharmaceuticals, Inc.

Completed

A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Myelofibrosis | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Myeloid Metaplasia | Philadelphia Chromosome-negative CML | Advanced Polycythemia

United States
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

Flunotinib Maleate Phase II Intermediate-High Risk Bone Fiber Clinical Trial

MF,PMF,PPV-MF,PET-MF

China
University Health Network, Toronto

Recruiting

A Pan-Canadian, Investigator Initiated Clinical Trial With Focal IRE Directed to Intermediate-Risk Prostate Cancer (WIRED)

Prostate Cancer

Canada
Fujian Medical University Union Hospital

Recruiting

Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Urinary Bladder Neoplasms | Treatment Outcome | Neoplasm Recurrence, Local | Multicenter Study | Immunotherapy, Active | BCG Vaccine

China
Ning Xu
The First Affiliated Hospital of Nanchang University; Zhongshan Hospital Xiamen... and other collaborators

Not yet recruiting

Posterior Extra-fascial RARP in Intermediate or High Risk Prostate Cancer

Prostate Cancer | Surgical Procedure, Unspecified
University of Kansas Medical Center

Not yet recruiting

Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

Myelofibrosis，MF
Sidney Kimmel Comprehensive Cancer Center at Johns...
Janssen Research & Development, LLC

Not yet recruiting

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Lymphoma | Multiple Myeloma | Hodgkin Lymphoma | Myelofibrosis | Non Hodgkin Lymphoma | Chronic Myeloid Leukemia | Hematologic Malignancy | Aplastic Anemia | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Bone Marrow Transplant Rejection | Acute Lymphoblastic Leukemia (ALL), Adult
NYU Langone Health

Recruiting

ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer

Prostate Cancer

United States
The First Affiliated Hospital of Soochow University

Recruiting

Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients

High Risk Acute Myeloid Leukemia | Intermediate Risk Acute Myeloid Leukemia

China
Supergene, LLC

Not yet recruiting

Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism

Pulmonary Embolism

Russian Federation
Rennes University Hospital

Not yet recruiting

Medico-economic Evaluation of Robot-assisted Laparoscopy Compared With Conventional Laparoscopy in Hysterectomy for Endometrial Cancer. (ROBOT-ECO-GYN)

Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma

France
UroGen Pharma Ltd.

Not yet recruiting

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (UTOPIA)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma
Hoffmann-La Roche

Recruiting

A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator)

Solid Tumors

Spain
Unidade Local De Saúde Do Norte Alentejano
NOVA Medical School

Recruiting

Opportunistic Gastric Cancer Screening (ROCGAS)

Gastric Cancer

Portugal
AOP Orphan Pharmaceuticals AG
GCP-Service International Ltd. & Co. KG; ANOVA CRO s.r.o.; PharmaLex Belgium; Aixial...

Recruiting

Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients (TripleTRE)

Pulmonary Arterial Hypertension

Austria, Spain, France, Germany, Italy, Czechia, Hungary, Poland, Portugal, Romania
IRCCS Sacro Cuore Don Calabria di Negrar

Not yet recruiting

Low and Intermediate Risk oliGometastatic coloREctal cancEr patieNts Treated With Stereotactic ABlative Radiotherapy (GREENLaIT-SABR)

Colorectal Cancer

Italy
ANRS, Emerging Infectious Diseases

Not yet recruiting

Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France. (CABOPrEP)

Prevention

France
British Columbia Cancer Agency
University of British Columbia; Vancouver Prostate Centre; BC Cancer Foundation

Recruiting

Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer (BrachyTRACKS)

Localized Prostate Carcinoma

Canada
Sunnybrook Health Sciences Centre

Recruiting

De-escalated Dose SBRT in Localized Prostate Cancer (DESTINATION-MRL)

Prostate Cancer

Canada
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital, Sun Yat-Sen University; First Affiliated Hospital... and other collaborators

Recruiting

TEER for Severe DMR of Low to Intermediate Surgery Risk

Mitral Regurgitation

China
Niguarda Hospital

Recruiting

Ultrasound-assisted, Catheter-directed Thrombolysis for Acute Intermediate-high-risk Pulmonary Embolism (USAT IH-PE)

Pulmonary Embolism

Italy
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Non-Invasive Biomarkers in Prostate Cancer Disease Management

Prostate Cancer

United States
NHS Lothian

Not yet recruiting

The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance (PRECISION)

Low Risk Prostate Cancer | Intermediate Risk Prostate Cancer | Localized Prostate Cancer
CG Oncology, Inc.

Recruiting

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Bladder Cancer | Urothelial Carcinoma | Urologic Cancer | Non Muscle Invasive Bladder Cancer

United States
Centre Hospitalier Universitaire de Nīmes

Recruiting

Impact of Training on the Use of Software and Digital Monitoring Tools During General Anesthesia for Intermediate/Major-risk Surgery on Morbidity and Mortality at 28 Days (AoA QUALITY)

All Conditions Requiring Non-cardiac Surgery

France
Yale University
Pfizer

Recruiting

The SUGAR Study: (SBRT and Ultrashort GnRH Antagonist-Relugolix) for Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer

Prostate Cancer

United States
Lantheus Medical Imaging

Recruiting

PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer (MIRROR)

Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Recruiting

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myelodysplastic Syndrome | Clonal Cytopenia of Undetermined Significance

United States
University Health Network, Toronto
Medical College of Wisconsin Cancer Center, Allegheny Health Network, Austin...

Recruiting

MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach (MAESTRO)

Anal Squamous Cell Carcinoma

Canada, Australia, United States
St. Jude Children's Research Hospital

Recruiting

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Rhabdomyosarcoma

United States
HTA Co., Ltd.

Recruiting

Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer

Prostate Cancer

China
Niguarda Hospital

Recruiting

Ischemic And Bleeding Risk Assessment After TAVR (FOCUS ONE)

Aortic Valve Stenosis | Transcatheter Aortic Valve Replacement

Italy, Belgium, Czechia, Chile, Spain
Center for International Blood and Marrow Transplant...
National Marrow Donor Program

Recruiting

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis (OPTIMIZE)

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Acute Leukemia | Myeloproliferative Neoplasm | Pro-Lymphocytic Leukemia

United States
The First Hospital of Jilin University
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

Diffuse Large B-cell Lymphoma

China
Qilu Hospital of Shandong University

Recruiting

Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Bladder Cancer

China
IRCCS San Raffaele

Recruiting

24 Gy in One Fraction Urethral-sparing "HDR Like" SBRT for Prostate Cancer (PRO-FAST)

Localized Prostate Carcinoma

Italy

Search clinical trials for: Intermediate risk myelofibrosis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations